Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, describes a recent study that aimed to detect early recipient predictors of neurotoxicity following CAR-T infusion, which remains a significant challenge. Serum samples from 79 patients with pre-B cell leukemia that had received CD19-directed CAR T-cell therapy were screened using an OLINK-proteomic platform, which led to the identification of several neuroprotective analytes. These recipient markers offer the potential to predict risk of neurotoxicity following CAR T-cell infusion and could enable the development of preventative strategies. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.
Jaap Boelens has served as a consultant for: BlueRock, Omeros, Sanofi, Advanced Clinical, AvroBio, Race Oncology and Medexus.